The establishment of a hub differential gene model to predict prognosis in stage II and III right- and left-sided colon cancer patients

被引:0
|
作者
Zhou, You-Tao [1 ]
Lin, Zi-Kai [1 ]
Shi, Man-Jie [1 ]
Yang, Cui-Yan [2 ]
Wei, Jia-Liang [3 ]
Ke, Chuan-Feng [2 ]
机构
[1] Guangzhou Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Dept Gen Surg, Affiliated Hosp 1, Guangzhou, Peoples R China
关键词
Hub; regression; principal component analysis (PCA); correlation; survival; COLORECTAL-CANCER; SURVIVAL;
D O I
10.21037/atm-21-6163
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: It is now recognized that the symptoms of colon cancer differ according to whether the tumor is located on the left or right side of the patient. The results of the present study point to the differences in the tissue and embryonic origins of left-and right-sided colon cancer that cause the variations in molecular typing. The research purpose of this study is to establish a core differential gene scoring model and proved its effect. Methods: We downloaded transcriptome data and clinical information from The Cancer Genome Atlas (TCGA). A total of 243 patients in stages II and III were grouped according to the colon cancer site. Then we screened for differential transcriptome products. The corresponding differential gene were performing a corresponding protein interaction analysis. We used 12 algorithms in Cytoscape to calculate the hub genes and a total of 37 hub genes were obtained finally. We extracted the first principal component value (PC1) of the hub genes to evaluate the effectiveness of screening. Cox regression analysis was performed for the differential genes. Finally, we performed a prognostic analysis on right-sided colon cancer patients using the BST2 gene, PC1 and relevant clinical information. Results: After screening for differentially expressed genes, 37 hub genes were obtained with appropriate algorithms. PC1 showed differences in hub genes between left-and right-sided colon cancer patients. BST2 and 31 other genes were identified as significant by Cox regression analysis and were significantly mutated in patients with right-sided colon cancer. Finally, we selected the BST2 gene and relevant clinical information as the prognostic factors to build a scoring model. The prediction effect of the model was satisfied. Conclusions: We constructed a prognostic model based on BST2, PC1, and other relevant clinical information and proved its good effect.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Factors Determining Postoperative Ileus After Surgery for Colon Cancer: Comparison of Right- and Left-Sided Resections
    Adamova, Zuzana
    Filova, Michaela
    Slovacek, Radim
    SURGICAL TECHNOLOGY INTERNATIONAL-INTERNATIONAL DEVELOPMENTS IN SURGERY AND SURGICAL RESEARCH, 2022, 40 : 140 - 146
  • [32] Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data
    Weiss, Jennifer M.
    Schumacher, Jessica
    Allen, Glenn O.
    Neuman, Heather
    Lange, Erin O'Connor
    LoConte, Noelle K.
    Greenberg, Caprice C.
    Smith, Maureen A.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (06) : 1781 - 1791
  • [33] Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data
    Jennifer M. Weiss
    Jessica Schumacher
    Glenn O. Allen
    Heather Neuman
    Erin O’Connor Lange
    Noelle K. LoConte
    Caprice C. Greenberg
    Maureen A. Smith
    Annals of Surgical Oncology, 2014, 21 : 1781 - 1791
  • [34] Fall of another myth for colon cancer: Duration of symptoms does not differ between right- or left-sided colon cancers
    Ozturk, Ersin
    Kuzu, Mehmet Ayhan
    Oztuna, Derya
    Isik, Ozgen
    Canda, Aras Emre
    Balik, Emre
    Erkasap, Serdar
    Yoldas, Tayfun
    Akyol, Cihangir
    Demirbas, Sezai
    Ozogul, Bunyamin
    Topcu, Omer
    Gedik, Ercan
    Baca, Bilgi
    Erguner, Ilknur
    Asoglu, Oktar
    Erkek, Bulent
    Yilmazlar, Tuncay
    Reis, Erhan
    Gencosmanoglu, Rasim
    Aslar, Ahmet Kessaf
    Konan, Ali
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (08): : 686 - 694
  • [35] COMPARISON OF CT-BASED RADIOMICS SIGNATURE BETWEEN LEFT-SIDED AND RIGHT-SIDED OF STAGE III COLON CANCER.
    Li, Y.
    Eresen, A.
    Zhang, Z.
    Lu, Y.
    DISEASES OF THE COLON & RECTUM, 2019, 62 (06) : E322 - E322
  • [36] Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival
    Benedix, Frank
    Kube, Rainer
    Meyer, Frank
    Schmidt, Uwe
    Gastinger, Ingo
    Lippert, Hans
    DISEASES OF THE COLON & RECTUM, 2010, 53 (01) : 57 - 64
  • [37] HLA class II polymorphisms as prognostic biomarkers for right and left-sided colon cancer
    Attia, Amani
    Lagha, Awatef
    Mezlini, Amel
    Ghazouani, Ezzedine
    Yacoubi-Loueslati, Besma
    Namouchi, Imene
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2024, 39 (01): : 40 - 51
  • [38] The prognostic significance of the expression of monocarboxylate transporter 4 in patients with right- or left-sided colorectal cancer
    Abe, Yukio
    Nakayama, Yoshifumi
    Katsuki, Takefumi
    Inoue, Yuzuru
    Minagawa, Noritaka
    Torigoe, Takayuki
    Higure, Aiichiro
    Sako, Tatsuhiko
    Nagata, Naoki
    Hirata, Keiji
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (02) : E49 - E55
  • [39] Prognostic Significance of Mitochondrial Transcription Factor A Expression in Patients with Right- or Left-sided Colorectal Cancer
    Katsuki, Takefumi
    Nakayama, Yoshifumi
    Akiyama, Masaki
    Sawatsubashi, Yusuke
    Nagata, Jun
    Minagawa, Noritaka
    Torigoe, Takayuki
    Izumi, Hiroto
    Kohono, Kimitoshi
    Hirata, Keiji
    ANTICANCER RESEARCH, 2018, 38 (01) : 569 - 575
  • [40] Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection
    Peng, Jianhong
    Li, Cong
    Wang, Fulong
    Zhang, Huizhong
    Xiao, Weiwei
    Li, Hui
    Lu, Zhenhai
    Pan, Zhizhong
    Wu, Xiaojun
    Zhang, Rongxin
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2095 - 2103